EGFR and non-small cell lung carcinoma: In summary, compared with adjuvant chemotherapy or placebo treatment, adjuvant EGFR‐TKIs significantly improved the DFS in EGFR‐mutant NSCLC patients with stage IB–IIIA disease who had undergone radical resection.